The Latin American peptide therapeutics market is forecasted to grow at a prominent CAGR from 2024 to 2029.
The key factors driving the market's growth include the increased incidence of various disorders such as cancer, gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others, as well as the availability and development of advanced drugs for treatment. In addition, the market's growth is also associated with increased investments in R&D for drug discovery and the presence of a strong product portfolio in the market. In addition, the increase in clinical trials in the market also boosts the Latin American peptide therapeutics market during the forecast period.
Since 2019, more than $ 3 billion has been invested in companies involved in developing various types of peptide drugs. In addition, the market is experiencing significant associative activity; recently, players in this industry signed several licensing agreements focused on the development and commercialization of drugs. Due to their proven pharmacological value, the demand for peptide drugs is undoubtedly expected to increase in the coming years.
Advances in technology have been beneficial in reducing the overall costs involved in the production of peptide therapies. This has prompted manufacturers and suppliers to pioneer new ways of making peptide therapies and tackling long and complex peptide chains. The radical shift towards hybrid technologies to reduce the strain on resources is likely to boost the short term of the Latin American peptide therapeutics market.
The Latin American peptide therapeutics market is expected to be hampered by the low chemical and physical stability of natural peptides and their limited half-life in circulating plasma. Additionally, since the peptide drugs are administered by injection, low oral availability and poor penetration of intestinal mucosa are expected to limit market growth in the near future.
Generic
Metabolic
Cardiovascular Disorder
In-house
Outsourced
Parenteral Route
Oral Route
Solid Phase Peptide Synthesis (SPPS)
Liquid Phase Peptide Synthesis (LPPS)
Brazil
Mexico
The market's growth is driven by factors such as increasing awareness levels related to peptide therapies, the growing need for diagnostics for cancer and other diseases, and the growing biotechnology industry.
Contract Manufacturing Organizations (CMOs) that provide end-to-end services to biotech and pharmaceutical companies are getting a lot of attention because they provide a better manufacturing and fulfillment experience. Peptide therapy market players are placing more emphasis on outsourcing drug manufacturing to CMOs to reduce operating expenses. The manufacturing of peptide therapies offers limited space for players to develop distinctive strategies to secure a competitive advantage. In addition, rising contract manufacturing allows market players to add technical resources to their existing business models.
The high prevalence of cancer and the increasing incidence rate of new cancer cases are expected to drive the market in Mexico during the forecast period. On the other hand, other peptide therapeutic drugs recently introduced or in advanced stages of clinical trials are expected to retain a significant share of the global peptide therapy market at the end of the forecast period. Additionally, the peptide therapeutics market in Argentina is expected to grow significantly during the forecast period. The rise of biotechnology companies and increasing healthcare spending by government authorities, the increasing prevalence of cancer and nervous system disorders are some of the factors that are expected to drive demand for Latin American peptide therapeutics in the future.
Some of the key players operating in the Latin American peptide therapeutics market profiled in this report are Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region